drugset

drugset / Trial / NCT00843518

Treatment for Aggression and Agitation in Patients With Alzheimer's Disease

NCT00843518 ↗

Phase 2 Completed 132 enrolled Eli Lilly and Company

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether this drug can help symptoms of aggression and agitation in participants with Alzheimer's disease.

Timeline

Start: 2009-02
Primary completion: 2011-06
Completion: 2011-06

Outcome

Missed primary endpoint

paper Both groups improved on the NPI-4-A/A, but without group differences. PMID 23257314 ↗

Publications

Trzepacz PT, Cummings J, Konechnik T, Forrester TD, Chang C, Dennehy EB, Willis BA, Shuler C, Tabas LB, Lyketsos C. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. Int Psychogeriatr. 2013 May;25(5):707-19. doi: 10.1017/S1041610212002141. Epub 2012 Dec 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MIBAMPATOR	Small molecule	3 mg	Oral

Indications